Kornimate/medical-research-clean huggingface dataset:
platelet activation in delayed cerebral ischemia secondary to aneurysmal subarachnoid hemorrhage

Conditions: Aneuvrysmal Subarachnoid Hemorrhage; Delayed Cerebral Ischemia; Endotheliopathy; Platelets Kinetic

Summary: aneurysmal subarachnoid haemorrhage is a complex pathology, the pathophysiology of which is still imperfectly understood. its morbidity and mortality remain significant. in addition to the damage sustained by the brain in the immediate aftermath of aneurysmal rupture, which is inaccessible to life-saving treatment, a significant proportion of lesions occur at a distance from the initial event. delayed cerebral ischaemia is one of the most morbid complications. it combines an inflammatory pattern with vascular dysfunction and neuronal excitotoxicity, leading to avoidable secondary neuronal loss. vascular dysfunction is mediated by a loss of homeostasis between endothelial cells and figurative blood cells, including platelets. however, the interrelationship between these elements and the precise chronology of the dysfunction remain imperfectly described to date. it therefore seems appropriate to propose temporal monitoring of platelet activation kinetics over time, combined with concomitant collection of markers of endothelial damage, in order to clarify the vascular chronobiology of this pathology.


Eligibility criteria:
inclusion criteria: * male and female adults ≤18 years of age. * hospitalised in the neurological intensive care unit of the pierre wertheimer hospital of the hospices civils de lyon following an aneurysmal meningeal haemorrhage of any modified fischer score, previously diagnosed by cerebral ct scan. * patients admitted to the neurological intensive care unit or the nicu of the pierre wertheimer hospital of the hospices civils de lyon for an intra-parenchymal haematoma. * patient who has been informed and has formulated his/her non-opposition, or close relative of the patient who has been informed and has formulated his/her non-opposition. * affiliated to a social security scheme. exclusion criteria: * non-aneurysmal sah * ischaemic stroke * patients with previously known platelet function disorders * pregnant or breast-feeding women * patients under legal protection (guardianship, curatorship, safeguard of justice) * patients under compulsory psychiatric care * patients taking part in a study which may interfere with the present study

Keywords: asha dci endotheliopathy platelets
intramedullary fixation of humerus fractures

Conditions: Humeral Fractures; Pathological Fractures

Summary: the purpose of the study is to evaluate the safety and efficacy of the composite nail - the quantum interlocking intramedullary nailing system in the reduction of humeral fractures.

the study will include 20 patients who have an acute mid shaft diaphyseal humeral fracture due to injury. the patients will undergo lateral and ap x- ray evaluation of the fracture. following general anesthesia, closed reduction of the fracture will be performed. it will be followed by nail insertion, percutaneously, according to standard surgical techniques, with the help of the insertion handle. following insertion the nail will be locked both distally and proximally using interlocking screws. the nail and screws insertion will be monitored by fluoroscopy. patients will remain under follow up for 6 months following the procedure. in the follow up sessions the fracture will be evaluated by fluoroscopy or x-ray for correct bone alignment, callus formation, and fracture union.

Eligibility criteria:
inclusion criteria: * above 18 years old. * mid shaft diaphyseal fracture * acute fracture exclusion criteria: * patients with metabolic or hormonal diseases that could affect bone healing such as diabetes. * ongoing infection in fracture site.
validation of algometry for use in the human foot

Conditions: Normative Algometric Pressures; Foot Pain

Summary: the primary aim is to examine whether there is a consistent range of pressure threshold values for the asymptomatic foot.previous studies established the inter/intra-clinician reliability of pressure threshold measuring and have established a normative range of values within the trunk and upper body. since the establishment of these values, pressure threshold testing has been used extensively in the head, neck, shoulders and spine as a clinical tool and a research aid. there has been little work using it in the lower limb and there are no guideline measurements for the clinician. by establishing a range of values for the foot,this study will enable the clinician to employ pressure threshold measuring as a clinical tool to easily and accurately identify areas of dysfunction and to objectively measure the effectiveness of treatment. it will allow the clinician to establish a degree of improvement or deterioration as it occurs in a patient's condition. secondary aims are to examine whether there is a correlation between visual analogue pain scale (vas) scores and algometric pressure threshold scores for subjects with forefoot pain. this will help validate the tool for use in the foot. since vas is well documented and validated, this study will examine whether there is a correlation between vas and algometry and whether there are gender or age differences in the range of measurements obtained. these areas have been addressed in previous studies but results have been contradictory and inconclusive and none of the previous studies focused on the foot. an asymptomatic group of 384 subjects \& symptomatic group of 160 subjects shall be selected from those attending a podiatric clinic for routine foot care who meet the inclusion criteria . outcome me will be algometric pressure threshold testing, visual analogue pain scales and foot function index questionnaires.


Eligibility criteria:
inclusion criteria: * all patients attending a local podiatric clinic for routine nail care or complaining of forefoot pain exclusion criteria: * forefoot surgery * diabetes * rheumatoid arthritis * osteopenia * all subjects with a diagnosed neurological condition * chronic pain at any body location * fibromyalgia

Keywords: algometry pain vas
endoscopic balloon dilatation combined with prp injection in colonic stenosis in crohn's disease

Conditions: Crohn Disease

Summary: the aim was to investigate whether endoscopic balloon dilatation combined with prp injection can help prevent or prolong restenosis in patients with crohn's disease with colonic stenosis, and to explore the concentration of prp. the study was a single-center, randomized, non-controlled study. experimental group of patients underwent endoscopic balloon dilation and submucosal injection of prp (prp prepared by the blood transfusion department of our hospital) at the wound edge, historical control was used, and the patients included in the study were randomly divided into high concentration group and low concentration group.


Eligibility criteria:
inclusion criteria: * diagnosed as cd; * stenosis of the colon was found during colonoscopy, and surgery was not considered for the time being; ③ imaging stenosis was found, that is, cte suggested stenosis with proximal intestinal dilatation \>3cm; * narrow length \<5cm; ⑤ the patients agreed to undergo endoscopic balloon dilatation and voluntarily signed the informed consent to participate in this study, and were capable of complying with the agreement. exclusion criteria: * the patient has contraindications for endoscopic therapy, such as coagulation disorder, severe cardiopulmonary dysfunction, active bleeding, and inability to cooperate. * deep and large active ulcer was found in the stenosis; * \< 18 years old; ④ foreign patients; ⑤ patients with a history of malignant tumors, including melanoma (except local skin cancer); ⑥ pregnant or nursing patients; ⑦ patients who could not be followed at all nodes of the primary outcome indicator; other diseases that researchers believe could put patients at risk; ⑧ other diseases that researchers believe could put patients at risk.
combined effects of global posture re-education and active cycle of breathing technique in copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the randomized controlled trial will involve 30 participants, with group a receiving gprm and acbt, while group b follows the conventional copd model that includes acbt only.assessments of heart rate, physical fitness, and quality of life will contribute to a nuanced understanding of joint function, informing future copd treatment paradigms.

the focus of this study will be on addressing the critical challenge of treating chronic obstructive pulmonary disease (copd), a globally prevalent and heterogeneous lung condition associated with substantial morbidity and mortality. with copd anticipated to become the leading global cause of death, this research will investigate a novel intervention that combines global postural retraining (gprm) and physical fitness, utilizing respiratory cycle technology (acbt). this study assumes to enhance heart rate, posture, and overall quality of life in individuals with copd. the randomized controlled trial will involve 30 participants, with group a receiving gprm and acbt, while group b follows the conventional copd model that includes acbt only. the study, utilizing nonprobability purposive sampling, will span six months to comprehensively evaluate cardiovascular, respiratory, and quality-of-life outcomes. exclusion criteria ensure a representative sample, excluding individuals with severe diseases or recent surgeries. the significance of this investigation lies in its potential to revolutionize copd treatment, offering a cost-effective approach that simultaneously enhances patient health. by targeting both biomechanical and respiratory aspects, the study aims to provide valuable insights into improving copd treatment strategies globally, with a focus on the combined effects of global postural retraining and active breathing techniques. assessments of heart rate, physical fitness, and quality of life will contribute to a nuanced understanding of joint function, informing future copd treatment paradigms.

Eligibility criteria:
inclusion criteria: 1. adults aged 40-75 years diagnosed with stable copd (according to gold guidelines). 2. patients of both genders 3. fev1: fvc ranging from 68 - 69%. 4. predicted fev1 of less than 70%. 5. willingness to participate exclusion criteria: 1. acute exacerbation of copd 2. participants with severe comorbidities, such as unstable cardiovascular diseases (e.g., recent myocardial infarction, uncontrolled hypertension) 3. participants diagnosed with respiratory conditions other than copd (such as asthma, interstitial lung disease) 4. individuals who have undergone major thoracic or abdominal surgery within the past three months 5. individuals with severe mental health conditions (such as uncontrolled psychosis or severe depression) 6. pregnant or lactating individuals.

Keywords: chronic obstructive pulmonary disease posture work of breathing
burn injuries during covid-19 pandemic and its influence on length of stay

Conditions: SARS-CoV-2 Infection

Summary: burn injuries were thought to be difficult to treat during the new corona virus epidemic. our goal is to determine the risk factors that influence length of hospital stay (los) of burn injured patients during covid -19 pandemic.

1. introduction / history the world is being attacked by the rapidly expanding severe acute respiratory syndrome coronavirus-2 (sars-cov-2) epidemic, which is exacerbating an economic crisis. sars-cov-2 is the cause of the coronavirus disease 2019 (covid-19). anaesthetists are at risk for contracting a virus while doing their regular duties because they frequently come into touch with respiratory droplets. all nations have put protective and preventive measures in place, forcing people to spend more time at home. a brazilian study discovered that during the covid-19 pandemic period, spending more time at home increased exposure to sanitizing products, which include ethanol and hydrogen peroxides that can cause burn injuries. aim of our study: our goal is to determine the risk factors that influence length of hospital stay (los) of burn injured patients during covid -19 pandemic. inclusion criteria: patients who had the burn graft surgery at al wakrah hospital; hamad medical corporation between from 1st of april to end of november 2020. planned number will include all covid-19 positive and negative subjects in this period. data source the electronic medical record (cerner) used in order to identify patients who match study defined criteria. the investigators can collect data directly from cerner to excel sheet variable abstraction patient demographic and clinical data will be collected including age, morbidities, presenting symptoms, physical examination, laboratory investigations, intraoperative data, type of surgery, postoperative course, survival, and length of hospital stay and follow up. in addition, the type of anesthesia is also included as factor for further complications ex general anesthesia, spinal or combined spinal epidural type. observation full reviewing of their medical illness and chart laboratory and investigations will be collected after getting approval of mrc and irb committee.

Eligibility criteria:
inclusion criteria: * all burn injuries required surgery with covid-19 positive or negative status exclusion criteria: * other surgery during covid-19 pandemic

Keywords: sars-cov-2 burn outcome perioperative length of stay
investigation of the immuno-regulation and viral hepatitis among patients with or after dengue fever infection

Conditions: Dengue Fever

Summary: the study will collect the blood samples from 350 healthy persons and 350 persons infected with dengue fever.

research has showed that clec5a interacts with dengue virion directly, and is responsible for dengue virus (dv)-induced dap12 phosphorylation. data suggests that clec5a is a potential therapeutic target for dengue hemorrhagic fever (dhf)/dengue shock syndrome (dss). this project will study the genes of clec5a, mannose receptor, dc-sign, nalp, decoy receptor 3 (dcr3), toll-like receptors(tlrs), and (nod)-like receptors (nlrs) for both df and dhf groups. in addition, serum level of decoy receptor 3 (dcr3) will be tested. the study will collect the blood samples from 350 healthy persons and 350 persons infected with dengue fever.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of dengue fever exclusion criteria: * none

Keywords: dengue fever, clec5a, mannose receptor, dc-sign, nalp, decoy receptor 3 (dcr3), toll-like receptors(tlrs), (nod)-like receptors (nlrs)
efficacy of magnesium sulfate on reducing renal colic in the emergency department

Conditions: Renal Colic

Summary: to determine if magnesium sulfate paired with an analgesic medication will improve patient pain from renal colic compared with analgesic alone.


Eligibility criteria:
inclusion criteria: * age \>18 years old and \<100 years old. * patients seen in the emergency department at henry ford macomb hospital. * patients that are a+ox3. * patients who have typical presentation for renal colic. exclusion criteria: * age \<18 years. * patients with a history of dementia, acute delirium or altered mental status. * patients with inability to consent to study or inability to fill questionnaire independently. * patients with chronic kidney disease and allergies to study drugs. * patients that are pregnant (women who are of child-bearing potential will be screened with a urine bhcg). * patients with stroke activation or symptoms. * patients with trauma activations. * patients over the age of 100 years old are excluded as they make up a small percentage of the population and may become identifiable because of their age. * imaging study does not show evidence of ureteral stone.
a study of hnc042 in healthy chinese subjects to evaluate the safety, tolerability, and pharmacokinetics

Conditions: Influenza

Summary: the purpose of this study is to evaluate the safety , tolerability and pharmacokinetics after multiple ascending of hnc042 given to healthy chinese volunteers, compared to placebo.


Eligibility criteria:
inclusion criteria: * volunteers can communicate well with the investigator, understand and comply with the relevant requirements of the study, understand and sign the informed consent * healthy adult male or female volunteers, age 18-65 years， * bmi between 19-26 kg/m2,and male body weight not less than 50.0kg,female body weight not less than 45.0kg . * volunteers with normal renal function exclusion criteria: * any condition that might interfere with the procedures or tests in this study * drug or alcohol abuse * smoking

Keywords: neuraminidase inhibitor
evolution of growth rate in children with growth retardation due to glucocorticosteroid therapy and treated by genotonorm

Conditions: Growth Hormone Deficiency

Summary: to estimate the evolution of height and growth rate over 5 years of growth hormone (gh) treatment to estimate the prognostic factors of growth rate with gh treatment to confirm the good clinical and biological safety of gh treatment in such children


Eligibility criteria:
inclusion criteria: * glucocorticosteroid treatment for 12 months at least * bone age \< 15 years for a boy and \< 13 years for a girl * child measured height \< - 2 sd, child currently treated by gh exclusion criteria: * known diabetes (type 1 or type 2) * a previous history of intolerance or hypersensitivity to the study drug or to drugs with similar chemical structures
covid-19 in pid survey

Conditions: Primary Immune Deficiency; COVID

Summary: with the emergence of sars-cov-2 and the covid-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals. whilst co-morbidities (such as diabetes, cancer, arterial hypertension, heart disease...) have been documented in people infected with sars-cov-2, there is currently no information on the consequences and outcomes for individuals with primary immunodeficiencies (pid). following the 1st phase of the survey (launched by isabelle meyts (esid), nizar mahlaoui (ceredih \& ipopi) and kate sullivan with stuart tangye (iuis), that gave an idea of the number of affected pid patients and the impact of sars-cov-2 and directly focusing on obtaining this top level of information), we are launching the 2nd phase: "copid19". copid19 survey is a secured online gdpr compliant platform based in paris (imagine institute). it has been approved by the paris-necker-enfants malades irb and ethics committee. however, this retrospective survey is designed for global distribution. data can be entered by a health care professional (mostly clinicians) through a personal login and password. each documenting person will have access to his/her own patients' data. copid19 require a greater level of information than the 1st phase. the ecrf will be open to evolutions depending on progresses in our knowledge of this pandemic.


Eligibility criteria:
inclusion criteria: * diagnosed with a primary immune deficiency * covid-19 (proven or probable) exclusion criteria: * secondary immune deficiency * other coronovirus infection
a study of rheumatoid arthritis patients on adalimumab to evaluate quality of life variables, effects on work productivity and functional outcomes in malaysia

Conditions: Rheumatoid Arthritis

Summary: an observational, non-interventional study on social, economic and quality-of-life outcomes of adalimumab use in participants with moderate to severe active rheumatoid arthritis.

this study was designed to evaluate adalimumab therapy in malaysia on participants' quality of life (qol) using non-invasive epidemiological methods like the health assessment questionnaire - disability index (haq-di), the health assessment questionnaire visual analog scale (haq-vas), and the health assessment questionnaire short form 36 (sf-36). the primary objective of the study was to evaluate the changes in qol outcomes in anti -tnf naïve malaysian ra patients after 6 months of adalimumab treatment. the secondary objectives of this study were to evaluate the changes on qol outcomes after 1 month and 3 months of adalimumab treatment; and provide an assessment of the safety and tolerability of adalimumab in anti tnf naïve malaysian rheumatoid arthritis patients.

Eligibility criteria:
inclusion criteria: * patients 18 years of age and older with a diagnosis of rheumatoid arthritis for at least 3 months according to the american college of rheumatology (acr) criteria * patients who have not been instituted on any anti -tumour necrosis factor (anti-tnf) agents prior to inclusion into this study (anti-tnf naïve patients). only anti-tnf naive rheumatoid arthritis patients who are scheduled to begin humira treatment, according to the relevant summary of product characteristics, on the basis of their own physician's judgment (and on the current clinical practice), will be selected for inclusion in this study * patients not included in other clinical/observational trials * patients providing a written informed consent before the enrollment in the study exclusion criteria: * refusal to participate in the study or to sign the informed consent * contraindications to adalimumab according to the terms of the local marketing authorization (label)

Keywords: product surveillance postmarketing
role of oxidized regenerated cellulose (orc) applied to "dirty" surgical wounds

Conditions: Infections

Summary: the purpose of this study is to determine whether oxidized regenerated cellulose (orc) is effective to reduce the risk of surgical site infections (ssi).

surgical site infections (ssi) have significant clinical and economic repercussions since they still are the most common cause of nosocomial infections in surgical patients. it is important to bear in mind the growing number of ssi due to antibiotic-resistant microorganisms.

Eligibility criteria:
inclusion criteria: * have an ileostomy or a colostomy * are candidates for an elective surgical procedure of ostomy closure exclusion criteria: * immunodeficiency * chronic use of corticosteroids or antibiotics * chemotherapy and/or radiotherapy in the last 30 days before closure of the stoma * concomitant foci of infection

Keywords: orc (oxidized regenerated cellulose) ssi (surgical site infections)
detection of aggressive breast tumors using tc-99m-nc100692

Conditions: Breast Cancer

Summary: the purpose of this study is to compare two types of radioactive drugs to see if they provide the same or different information about any disease that may be present in the participants breast.


Eligibility criteria:
inclusion criteria: * have a lesion on mammogram, ultrasound or breast mri that measured \< 15 mm in diameter, is considered suggestive or highly suggestive of malignancy according to the breast imaging reporting and data system atlas criteria (birads 4b, 4c or 5), and is scheduled for biopsy (needle biopsy and/or surgical biopsy). or * have a lesion on mammogram, ultrasound or breast mri that measured \> 15 mm in diameter, is known to be malignant and is scheduled for surgery. * patient age \> 18 years of age. * have a negative pregnancy test on the first day of the study, or must be postmenopausal or surgically sterilized. exclusion criteria: * patients will be excluded if they have a small lesion (\< 15 mm) and have undergone prior needle biopsy of the lesion (such biopsy may effectively remove all or part of the lesion and angiogenesis associated with wound healing might confound imaging results with 99mtc-nc100692). * patient's pregnancy is not negative on the first day of the study, or the patient is unable to complete the pregnancy test * patient is unable to sit on a chair for 40 minutes

Keywords: mbi molecular breast imaging breast breast cancer molecular imaging